Abdominal aortic aneurysms are often fatal due to atherosclerosis, thromboembolism, rupture, and hemorrhage, however, treatment is limited to expectant monitoring and surgical intervention. Inflammation is detected in aneurysms and in plaque with associated increased apoptosis, chemokines, cytokines, hemorrhage, and thrombosis. We compared treatment with three different myxomavirusderived anti-inflammatory proteins targeting apoptosis, thrombosis, and chemokine pathways. The effect of each protein on aortic dilatation and plaque growth was assessed after angioplasty in Apolipoprotein Enull mice. Four myxomavirus-derived proteins were studied; Serp-l a serine protease inhibitor (serpin) targeting thrombotic and thrombolytic proteases, Serp-2 a cross-class serpin inhibiting granzyme Band caspases land 8, M-T7 a broad spectrum C, CC, and CXC chemokine inhibitor, and Rl7lE, an inactive M-T7 mutant. Cell invasion, elastin breaks, plaque progression, and aortic dilatation were significantly reduced by Serp-l, Serp-2, or M-T7 protein treatment, but not by Rl7lE. PCR array analysis detected altered expression of a group of shared 40 apoptotic genes in monocytes after treatment with each active protein, but not Rl71E. Interference with inflammatory cell responses, through highly divergent inflammatory response pathways, produces similar reductions in monocyte invasion, arterial dilatation, and plaque growth potentially through modified expression of apoptotic genes.
Although the risk associated with atherosclerotic cardiovascular disease is now markedly improved, the incidence ofabdominal aortic aneurysms (AAAs) is increasing (1-7). AAA is a localized dilatation of the aorta with diameter greater than 3 em (or more than 50% increase) with loss of medial elastin and associated cell death (apoptosis). There is often a marked increase in local atherosclerotic plaque and thrombosis at sites of aneurysmal dilatation. Undiagnosed AAAs affect 5% of men over 65 years of age, often causing sudden death (1-3). Nearly 2 million Americans are at risk for AAAs, with 4-8.9% prevalence worldwide, increasing as the population ages (1). Sudden rupture of the destabilized aneurysmal vessel has 50% to 80% associated mortality (1-3). While control of atherosclerotic risk factors, e.g. smoking, hypertension and hyperlipidemia, is recommended for patients with AAAs, efficacy of preventative treatment varies (1) (2) (3) (4) (5) . Expectant monitoring of aneurysm progression with eventual surgical repair or urgent surgery for aneurysm rupture remains the standard of care, but has higher associated risk. Additionally, many aneurysms are silent with unheralded rupture. Surgical repair can also induce further hazards due to arterial damage, recurrence or leak after repair, thrombotic occlusion, or neurological damage. Recurrence is reported to be particularly high in subsets of patients with highly inflamed aneurysms.
The maturation of aneurysms occurs through endothelial dysfunction, chronic inflammation, matrix (collagen and elastin) degeneration, apoptosis, and vascular remodeling (3, 5) , sharing causative factors with atherosclerosis (5, 6) . Inflammatory cell invasion occurs in all arterial layers and is accompanied by elastin fragmentation, resulting in large, fragile vessel walls at risk for rupture and hemorrhage (7) . Inflammatory cells that invade the vessel include macrophages, CD8+ cytotoxic T lymphocytes (CTL), and CD4+ T helper cells (5, 8) as well as neutrophils, fibroblasts, and mast cells (5, 6) . Enlargement and degradation of the arterial wall is due, in part, to destruction of elastin and collagen by matrix metalloproteinase enzymes (MMPs) that are activated by fibrinolytic serine proteases known as tissue-and urokinase-type plasminogen activators (tPA and uPA, respectively) (2, 6) . Proteasemediated degradation of structural proteins weakens the arterial wall and induces apoptosis of endothelial cells, vascular smooth muscle cells (VSMCs), and invading mononuclear cells, causing further inflammation and thinning of the arterial wall (2, 8, 9) .
Many of the proteolytic, inflammatory, and apoptotic responses driving atherosclerotic plaque development and rupture overlap with those causing aneurysms resulting in simultaneous progression of both atherosclerosis and aneurysmal dilatation (1-5). Apoptotic cells in the arterial wall release cytokines and chemokines and enhance inflammatory cell activation (6, 9) . Chemokines from activated cells attract inflammatory cells into the arterial wall (6) and, together with breaks in the elastin connective tissue layers, induce cell invasion and arterial dilatation. Apoptosis of VSMCs reduces secreted elastin and collagen in the arterial wall with reduced tensile strength of the vessel wall (5, 9) . Apoptosis of endothelial cells, macrophage, or T lymphocytes induces release of clotting factors and cytokines and produces pro-thrombotic and pro-inflammatory states (2, 7, 8) . Apoptosis in VSMCs is closely associated with aneurysm formation; however, the contribution of apoptotic inflammatory cells to aneurysm progression is less well defined. We have postulated that modulation of inflammatory cell responses through inhibition of a variety of protease or chemokine pathways has the potential to alter apoptotic responses, inflammation, plaque growth, and aneurysm formation.
Large DNA viruses, such as the poxviruses, encode a variety of proteins that have evolved to modify innate and acquired immune responses (10) . Myxoma virus is a lagomorph infecting, leporipoxvirus that expresses anti-inflammatory serpins and chemokine modulating proteins (CMPs), among other immune modifiers. Serine proteinase inhibitors, termed serpins, regulate thrombotic and apoptotic cascades along with multiple other pathways, representing up to 2-I0% of plasma proteins (11, 12) . CMPs, inhibit either chemokine binding to receptors or glycosaminoglycans (10, 11, 13, 14) . Myxomaviral proteins suppress host inflammatory responses during virus infections, acting as protective elements for the virus (10, II). These immunomodulatory viral proteins have become highly potent through natural selection, the virus having identified pivotal pathways required for effective blockade of host immune responses against the viral infection. Notably, when these proteins are knocked out in the virus, the viral infection becomes more benign (10, II).
When utilized as purified protein isolates, these anti-inflammatory proteins suppress disease progression in animal models of inflammatory vascular disease, specifically atherosclerosis and transplant rejection (10, 11, (13) (14) (15) (16) (17) (18) (19) (20) . Serp-I is a secreted 55kD serpin (serine proteinase inhibitor) that inhibits uPA, tPA, plasmin, and factor Xa (16, (18) (19) (20) . Serp-2 is a 34kD cross-class serpin that inhibits caspase I and 8 and granzyme B (15, 21) . M-T7 represents a separate protein class, inhibiting rabbit interferon gamma (IFNy) (13, 14, 17, 22) and a broad spectrum of C, CC, and CXC chemokines in a non-species dependent manner (13, 14, 17, 22) . In multiple animal models, Serp-1 reduced plaque growth and transplant vasculopathy (10, 11, 16, 18-20, 22, 23) and Serp-1 has been successfully tested in a clinical trial in patients with unstable coronary syndromes after stent implantation (24) . M-T7 and Serp-2 also reduced inflammation and plaque growth in models of atherosclerosis and transplant vasculopathy (11, 13-15, 17,22) . Inactive mutants of these proteins, however, do not block inflammation or plaque growth (14) (15) (16) .
We examined the relative efficacy of inhibition of differing innate immune pathways for prevention of arterial plaque growth and aneurysmal dilatation after balloon angioplasty injury in Apolipoprotein E deficient (ApoE-I-) mice in vivo and for modification of gene expression in human endothelial, monocyte, and T cells in vitro.
MATERIALS AND METHODS
All research protocols and animal care conform to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health and the Guiding Principles for Animal Experimentation of the University of Florida and were approved by the University's Institutional Animal Care and Use Committee.
Mouse aortic angioplasty model
Twelve-to 14-week-old Apolipoprotein E deficient (ApoE-I-) (Jackson Laboratory, Bar Harbor, Maine Strain: B6.129P2-Apoe<tmlUnc>/J) male mice were fed Atherogenic Rodent Diet ad libitum (Harlan, Madison, USA) starting 14 days before operation and until sacrifice (n = 63). C57Bl/6 wild type mice were fed normal diets (n = 15). Aortic balloon angioplasty was performed under general anesthesia (2: 1 ketamine xylazine) as previously described [40] . Serp-l (n = 14), Serp-2 (n = 5), M-T7 (n = 14) , saline (n = 21) or inactive M-T7 mutants R171E 
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C57Bl/6 10 4wk + I hematoma C57BI/6 5 4wk 61J.g or E209I (n = 9), in 0.1ml sterile saline were given by intravenous (i.v.) tail vein injection at the time of surgical wound closure (Table I) .
Buprenorphine was used for post-operative analgesia. To assess early changes after surgery and protein treatment, animals were sacrificed by 50 uL Pentobarbital Sodium (Bimeda-MTC Cambridge, Ontario, CA) intramuscular injection immediately after angioplasty (0 h) and at 24 h, 7 days, or 28 days post-surgery (Table I) . Prior studies have demonstrated no adverse effects and no increased mortality with Serp-l , Serp-2, or M-T7 treatment (11, [13] [14] [15] [16] [17] [18] [19] [20] [22] [23] [24] .
Source ofproteins.
Serp-I protein was expressed in Chinese Hamster Ovary cells (16, (18) (19) (20) 23, 24) and Serp-2 was His-tagged (His I0) at the amino-terminus, expressed from a vaccinial T7 vector in HeLa cells and purified as previously described (15) . M-T7 was expressed by vaccinia vector system in baby green monkey kidney cells (13, 14, 17, 22) , as previously described. For the preparation of an inactive M-T7 construct, recombinant His tagged M-T7 (M-T7-His 6x ) and selected site mutants R I71E and E209I were generated in a baculovirus mediated insect cell system. Details of the generation and expression of the point mutations and a detailed analysis of in vivo activity in mouse models in vivo and in cell activation assays in vitro are described elsewhere (14, 15) . In brief, C-tenninal His-tagged M-T7 was cloned into pcDNA3.1 by PCR and then subcloned into a pFastBacDual (Invitrogen, Carlsbad, CA, USA) expression vector containing eGFP (Enhanced Green Fluorescent Protein) reporter driven by the pIO promoter. Mutants were generated by mutagenic PCR of the M-T7 pFastBacDual construct and transformed into DHIOBac (Invitrogen, Carlsbad, CA, USA) cells to generate bacmids that were screened and purified using QIAprep Spin Miniprep Kit (Qiagen) ( 14) . Incorporation ofM-T7 was verified by PCR.
Histological. immunohistochemical. and morphometric analysis
Arterial specimens, 0.5-0.6 em in length, were harvested and cut into three equal length sections, fixed, and paraffin-embedded. Three 5-l-un sections were cut per specimen and strained (H&E, Masons Trichrome and: CD3; Cat # AB5690, CDllb; Cat # AB75476, Secondary anti-rabbit; Cat# AB80437; Caspase 3; # AB3623, secondary anti-rabbit-HRP Cat # AB80437. Abeam, Cambridge, MA, USA) (II, 13-17, 19-21,25, 26) . Aortic plaque areas were measured using an Olympus microscopy system standardized to the microscopic objective, as previously described (Image-Pro Plus V6.0, Georgia, MD) (II, 13-17, 19-21,25) . Aortic dilatation was measured both by IEL and EEL short and long axis diameters as well as IEL and EEL areas (25) measured at perpendicular sites in each arterial cross section using the same morphometric microscopy system.
Positively stained cells were counted in three high power fields (I OOX) for each arterial cross-section in each of the arterial layers (intimal, medial and adventitial layers) in all sections for each mouse after immune staining for sections isolated at 28 day follow-up. Elastin breaks were counted in high power fields in the medial layers throughout the whole section for each cross section from each mouse on Masson's trichrome stained sections for each mouse aorta and for each section. The entire arterial cross section was examined for elastin breakage to avoid errors due to the serpiginous nature ofelastin fibers.
Quantitative Real Time Reverse Transcriptase -Polymerase Chain Reaction (qRT-PCR)
For RNA isolation, 5xI0 6 Human umbilical vein endothelial cells (HUVEC), Jurkat T cells or THP-l cells (American Type Culture Collection, Rockville, MD, USA, TIB-202) were treated with saline or 10 IlM Camptothecin (CPT) in DMSO with and without either 500 ng Serp-1, Serp-2, or M-T7 per million cells. Treated cells were incubated for either 30 min or 4.5 h analysis endpoints. Equal quantities ofeDNA was mixed with SABioscience's premixed SYBR PCR mix, and applied to an apoptosis array (Cat. # PAHS-O 12). Plates were run on an ASI 7300 Real-time PCR Machine (Applied Biosystems, Foster City, CA, USA) according to the recommended protocol. Protein treatment gene expression data, as measured by Relative Quantity (RQ), was normalized first to GAPDH and then to the RQ of each gene from the CPT-only group. All studies were performed in triplicate.
Statistics
Data were compared by unpaired Student's t-test and analysis of variance (ANOVA) with Fisher's protected least significant difference (PLSD) post-hoc testing (Statview, SAS Institute, Cary, NC, USA) as previously described (11, 13-20, 22, 23) . Fold changes in gene expression were analyzed using ABI software (Carlsbad, California, USA), (P < 0.05 deemed significant).
RESULTS

Increased plaque and arterial dilatation in Apoli": mice after angioplasty injury
To assess atherosclerotic plaque development and arterial dilatation after balloon angioplasty, both wild type and hyperlipidemic mice were evaluated for aortic plaque area and diameter in wild-type mice ( Fig. I A) and ApoE· 1 • mice ( Fig. I  B) at 28 days post-angioplasty, Aortic dilatation was measured using IEL and EEL diameters together with elastic lamina fragmentation. Apoli" mice (N=12, Table I displayed spontaneous atheroma and aneurysm-like formation, however, plaque progression and arterial dilatation occurred more rapidly, at 4 weeks, with balloon injury than has been previously reported in non-injured Apolr" mice (25) .
Anti-inflammatory protein treatment reduces plaque growth and arterial dilatation
In a second series of experiments, three antiinflammatory myxomaviral proteins known to inhibit differing inflammatory pathways, were assessed for effects on plaque growth and arterial dilatation in ApoE· 1 • mice after balloon angioplasty injury. Mice were treated with a single i.v. bolus of one of the proteins immediately after angioplasty, or a saline control treatment (Table I) . Initially Serp-I that inhibits coagulation proteases and M-T7 that inhibits In contrast, treatment of C57BV6 mice with M-T7, after angioplasty did not significantly alter plaque growth, nor reduce arterial dilatation (data not shown). Mononuclear cell invasion was reduced from early follow-up at 24 hand 7 days to 28 days in the intimal (not shown) and adventitial layers ( Fig.   2B ) with protein treatment; at 28 days, this reduction was significant for Serp-I (N= 14, P :s 0.0013) and M-T7 (N=5, P:s 0.0030) treatments ( Fig. 2 B-F) .
In ApoE-1 -mice at 28 days, there was a significant reduction in EEL ( significantly reduced the lEL (P ::::0.0331) and EEL (P ::::0.0213) by 25% and 26%. Changes in lEL and EEL were not significant at earlier follow-up times (Fig. 2  G, H) . Similarly, no significant early differences were detected in saline or protein treatment ofApolr" mice for plaque area, lEL , or EEL measurements after angioplasty from 0 hours up to 7 days (P = NS) ( Fig. 2  A) . Changes in inflammatory cell invasion ( Fig. 2 B , C-F) as well as elastin breaks (Fig. 2 I) were assessed with Serp-l and M-T7 treatment. Serp-l ( Fig. 2 K) and M-T7 ( Fig. 2 L) significantly decreased elastic lamina breaks as measured on Masson 's Trichrome stained sections (at 7 days -Serp-l N=5, P :::: 0.0012; M-T7 N=5, P:::: 0.0059; Fig. 2 I) when compared to saline ( Fig. 2 I,J) . This reduction was not significant at later times . In summary, treatment with three viral anti-inflammatory proteins that target different inflammatory pathways, effectively reduced early inflammatory cell invasion and elastin breaks with late reductions in plaque growth and dilatation .
Treatment with an inactive mutant ofM-T7 does not reduce plaque or arterial dilatation In a separate set of studies treatment with inactive mutant s of M-T7 (M-T7 E2091 and R171E) was assessed after balloon angioplasty injury in Apofr 1-mice as a control to confirm that an inactive mutated protein would not produce a similar effect on arterial plaque growth and dilatation. Treatment with inactive point mutations ofM-T7 (M-T7 E2091 and R171E) did not reduce arterial plaque format ion ( Fig. 3 A) . Plaque area was equal in size when measured by plaque area (Fig. 3 A) and by intimal to medial thickness ratios after balloon angioplasty in ApoE-I-mice after treatment with E2091 (P = 0.789) when compared to saline treatment in the same model. Treatment with R 171E conversel y led to an increase in plaque size (P < 0017 , Fig. 3 A) , as previously reported (14) . Arterial dilatation was also unchanged with E2091 treatment (P = 0.509) and increased after R 171E treatment as measured by lEL area (P < 0.024, Fig. 3B ) and by arterial diameter measurements ( Fig. 3 B) 
Inflammatory cell invasion is reduced with viral immunomodulatory protein treatment
To confirm whether protein treatments reduced invasion of spec ific inflammatory cell types into the abdom inal aorta , CD 11 b+ macrophage and CD3+ T cell counts were measured by immunohistochemical staining. Anti-inflammatory protein treatments were assessed at 28 days to examine the potent ial for long- term effects on inflammatory cells in the arterial wall produced by treatment with the anti-inflammatory proteins. Positively stained cells were counted in each arterial layer. Mononuclear cell invasion was increased in Apof;" mice after angioplasty injury at 28 days when compared to C57/B16. On comparison to saline-treated ApoE -1-mice, saline-treated C57BI/6 wild type mice had significantly fewer CDY cells in the intimal ( Fig. 4A , P S 0.016), but not in the adventitial layers ( Fig. 4 B, P =0.297) .
For ApoE -1-mice at 28 days follow up, Serp-I (P SO.OOI), Serp-2 (P SO.020), and M-T7 (P s....0.007) treatments all significantly reduced CD3+ T cells in the intima ( Fig. 4 A) , whereas only Serp-2 (P S 0.006) and M-T7 (PS 0.008) significantly reduced adventitial CD3+ T-cells ( Fig. 4 B) . Serp-I treatment produced an insignificant trend toward reduced CD3+ T cells in the adventitia (P =0.082).
Conversely, for CD 11 b" macrophages in ApoE ·1· mice, none of the protein treatments significantly reduced macrophage invasion in the intima (Fig.   4 C) at 28days post treatment, although there was a trend toward a reduction with Serp-L Serp-I (P S 0.0163) did, however, significantly reduce adventitial macrophage counts ( Fig. 4 D) . Serp-2 and M-T7 produced a non-significant trend toward reduced adventitial Cd II b positive cell staining.
Viral anti-inflammatory protein treatment alters gene expression
Given the similar efficacy for the three antiinflammatory proteins on aortic plaque growth and aneurysm-like dilatation, effects of each protein on gene expression in human endothelial cells, monocytes and T cells, three known cellular mediators ofinflammatory responses, were examined in vitro. Cultured human cells were screened for shared gene response pathways targeted by all three proteins. Jurkat T cells, THP-I monocytes, and Human Umbilical Vein Endothelial Cell (HUVECs) were treated with Camptothecin (CPT), a topoisomerase inhibitor, to induce apoptosis and 
Fig. 5. Venn diagram demonstrating overlap ofgene expression changes in THP-J cells (A) or Jurkat T cells (B) after treatment with 3 viral proteins and CPTfor 30 min. The numbers in the diagram represent genes which experienced a greater than 2-fold change in expression compared to CPT treated cells. Averaged gene expression changes for all 3 protein treatments represent triplicate repeats for each cell analysis with each protein when compared to CPT alone are detailed in (C). Bolded genes indicate up-regulated genes.
co-treated with either saline or Serp-1, Serp-2, M-T7, or the inactive M-T7 R171E mutant (500 ng per 10 6 cells). Gene expression data, as measured by Relative Quantity (RQ), was normalized first to GAPDH and then to the RQ of each gene from the CPT-only group. The mean value for RQ for all three treatments compared to the control CPT treatment alone, for genes where all protein treatments had a demonstrated two-fold change, was then calculated. As cell death is now known to drive some aspects of vascular inflammation, plaque growth, and aneurysm formation, expression of a set of 96 genes in apoptosis were analyzed. Although greater and more consistent changes were detected in T cells by immunostaining after angioplasty, monocytes displayed more changes in gene expression in vitro. Despite the fact that these viral proteins target different molecular pathways in vivo, after 30 min of treatment, a cohort of 48 shared genes with similar changes in expression was detected in monocytes after treatment with the three active viral antiinflammatory proteins ( Fig. 5 A; Fig. 5 in endothelial cells nor in T cells (Fig. 5 B) . A few shared gene changes were observed for HUVEC cells with Serp-l and Serp-2 treatments at 30 min when compared to camptothecin treatment alone. Minimal shared changes were detected for all three cell lines at 4.5 h (data not shown). For Jurkat cells there were no genes with shared changes in altered expression at 30 min for all three treatments when compared to camptothecin treatment alone (Fig. 5 B) . Serp-l and Serp-2 did induce altered expression of three shared genes (FAS, BNIPl, TP53) and Serp-l and M-T7 did share one gene with altered expression (CARD6). FAS and TP53 were also seen in THP-I cells at 30 min treatment, but they were not affected in the same way; FAS and TP53 are up-regulated in Jurkat T cells and down-regulated in THPI monocytes. CARD6 was down-regulated in Jurkat cells at 30 min as in THP-I cells. For HUVECs treated with Serp-l or Serp-2, eight genes (BCL2L 10, BIRC8, FASLG, HRK, TNFRSFIIB, C027, TNFSF8, TP73) had shared similar changes at 30 min with THP I consensus genes, but none were shared with Jurkat gene changes .
Treatment with the inactive M-T7 mutant , M-T7 R171 E modified several of the shared cohort of 48 genes, leaving 40 genes shared by all three active antiinflammatory proteins with potential as regulatory targets for modification of inflammatory responses after treatment with each of the three proteins (Fig.  6) . In, brief, 8 genes are shared by M-T7 Rl71 E with Serp-l , Serp-2 and M-T7: CIOEA, CASP7, CLFAR, NAIP, BCL2L 10, BAK 1, BAX, BCL 10 (all analyzed with requirement for a minimal 2-fold change). There are 4 genes shared between Serp2 and the M-T7 R17lE mutant: TNFRSF9, BCL2L2 ,CASP8, TNFRSF9.
All three viral proteins demonstrated the capacity to regulate expression of a shared cohort of genes in THP-I monocytes. A closer look at the mean RQ ... ,.. . , values of the co-regulated genes (Fig. 4 C) indicates that many of these shared genes that are involved in triggering or repressing apoptosis are down-regulated when compared to the CPT-only control with a potential net effect of the viral protein treatments to decrease cellular apoptosis (Fig. 6 ).
Having detected both a reduction in inflammatory cell invasion and elastin breakage with associated reductions in plaque growth and arterial dilatation in vivo as well as associated gene expression changes in apoptotic human monocytes in vitro, we assessed apoptotic changes in the arterial wall after angioplasty injury and protein treatments, using active caspase 3 to indicate ongoing apoptosis.
Anti-inflammatory protein treatment reduced early caspase 3 activity
To assess the anti-apoptotic potential for each protein, Caspase 3 (Casp 3) levels were measured by immunostaining in aortic cross sections . Casp 3 expression varied with location and protein treatment ( Fig. 7 A Saline ; B Serp-l ; C M-T7). In the adventitia (Fig. 7 F) and media ( Fig. 7 E) , the greatest levels of positive cells were present at 24 h in saline treated mice with a reduction by 7 days. In the intima (Fig. 7 D) 
DISCUSSION
When fed normal chow, ApoE· 1 • mice, unlike their wild-type counterparts, spontaneously develop plaques and aneurysms (25, 26) . In this model of balloon angioplasty injury, ApoE· 1 • mice develop significantly more plaque (Fig. I A) and aortic dilatation at earlier times ( Fig. I C) than wild type mice. Our findings indicate that the aggressive inflammatory response and associated plaque growth in ApoE· 1 • mice potentially drive the aneurysm-like dilatations detected after balloon angioplasty (25, 26) .
Treatment with proven inflammatory cell inhibitors that target different molecular pathways reduced both aneurysm-like dilatation and plaque growth. These findings suggest that altering immune or inflammatory responses reduces both aneurysm formation and plaque growth, irrespective of the pathway targeted by the anti-inflammatory viral protein treatment used and suggesting a common response in the arterial wall.
Arterialdilatationandaneurysmfonnationareclosely associated with atheroma formation. Atherosclerotic lesions are also frequently closely associated with aneurysms in man. Whether arterial dilatation at sites of plaque growth represents a true aneurysm formation or simple arterial wall remodeling is not known. It is also not known whether aneurysm formation at sites of atheroma formation when compared to areas of aneurysmal dilatation alone without plaque growth may represent differing subspecies of aneurysms. In this model, however, we have detected both marked arterial dilatation at sites of plaque growth as well as local inflammatory cell invasion and elastin breaks suggestive of aneurysm formation,
We have demonstrated that the viral proteins Serp-l, Serp-2 and M-T7 significantly reduce inflammation, early elastic lamina breakage and late plaque growth and aneurysmal dilatation in this mouse model with balloon angioplasty injury. Serp-l has completed a phase II clinical trial, reducing markers for myocardial damage (24) and demonstrating that purified viral anti-inflammatory proteins can be used safely in both animals and man as therapeutic agents. Furthermore, prior work has demonstrated that inactive serpin controls, including myxomavirus Serp-l SAA (16) , vaccinia virus serpin CnnA (21) and Serp-2 reactive center mutants (15), do not alter inflammatory cell invasion or plaque growth. In this study and one prior study, treatment with two mutated M-T7 constructs (14) also did not reduce plaque growth nor arterial dilatation and, in fact, for the R 171E mutant both plaque and IEL areas were increased after balloon angioplasty in ApoE-I-mice.
We have examined Serp-l, Serp-2 and M-T7 as representative of highly active anti-inflammatory proteins that reduce arterial inflammation and plaque in order to identify shared mechanisms by which early treatments using biological agents with predicted short half-life can have prolonged efficacy. The halflife of Serp-l is known and has been measured as equal to 30 minutes up to 12 hours. However, this is a circulating half-life measurement and may not reflect cell or tissue half-life (10, 11, 24) . The doses used for each protein are based upon prior studies that have identified doses with biological efficacy in arterial injury models (13) (14) (15) . Prolonged reductions in inflammatory cell responses leading to reduced plaque growth may be initiated after single dose infusions of each of the proteins through targeted modulation ofprotease pathways that are responsible for initiating activation of the innate immune response or may be produced by altering expression of selected genes. Modulation of cellular activation may thus occur via inhibition of proteases that are extrinsic to affected cells and are responsible for downstream initiation of innate immune reactions or may function through interaction with and uptake of proteins interacting with select cell receptors. We postulated that, through comparative analysis of the three active anti-inflammatory proteins, central or pivotal regulatory pathways, not previously known, representing key steps in inflammatory responses might be identified and further that these newly identified pathways may provide new therapeutic directions in inflammation-based disorders.
To further examine potential shared pathways, specifically apoptotic pathways, in targeted inflammatory mononuclear cells, human cells in culture were assessed for selected changes in gene expression. This does not provide a direct link to responses in mice, but does provide the basis for detection of potential generic mammalian cell responses. This approach thus provides both information on possible effects on human cells and differential effects in cells involved in inflammatory cell responses in the arterial wall, albeit using human cells. Further work to assess individual mouse cell responses to the anti-inflammatory proteins will be required to compare effects on human and mouse cells.
Apoptotic cells in early plaques and arterial damage can release a powerful mix of proinflammatory molecules that exacerbate inflammatory cell invasion, plaque growth, artery dilatation and apoptosis, begetting a vicious cycle that can lead to aneurysm formation (1-7). Although all three proteins reduced COY T-cell invasion in the mouse aorta (significantly), but only produced a trend toward reducing CD 11 b" macrophage for two proteins, we detected a more consistent gene expression response in human monocytes than in Jurkat T cells or HUVEC after treatment with each of the active proteins. This difference may reflect an earlier response in monocytes, such that early inhibition of monocyte/macrophage activation may have greater downstream effects on arterial T-cell invasion, plaque growth and dilatation. These early changes in macrophage invasion may also represent altered levels ofactivation rather than altered numbers of invading cells. The THP-I gene expression changes underscore a possible pivotal effect on macrophage apoptosis in the arterial response.
Analysis of 96 genes by PCR array revealed consensus response genes for all three antiinflammatory treatments, highlighting 13 BCLfamily proteins and 9 TNF receptors and ligands, which have diverse roles in apoptosis ( Fig 4C) . For instance, BCL-family proteins BIK, BAG4, and BCLAFI were up-regulated in response to protein treatments: BIK is a pro-apoptotic protein, BCLAF 1 is a transcriptional repressor protein with proapoptotic effects, and BAG4 is purported to silence TNFR-l 's downstream signaling via down-regulated gene TNFSRFlA, culminating in anti-apoptotic effects (27) . In a similar manner, the 9 downregulated BCL-family proteins are also functionally diverse. The TNFR family has 9 genes significantly down-regulated, with only two TNF family proteins (DR6/TNFRSF2l and TRAF3) that are up-regulated after treatment with each of the three viral antiinflammatory proteins. The TNF family proteins and ligands are present in a wide variety of cell types and are also known to be responsible for diverse functions, including induction of apoptosis as well as inflammatory cell recruitment, inhibition of viral replication, and tumorigenesis (28, 29) .
Of note, down-regulated proteins include the death ligand (FasL) and its transmembrane death receptor (FAS) which are the main components of the Death Induced Signaling Cascade (DISC), the platform ofthe major extrinsic apoptosis cascade (30). Furthermore, c-FLIP, an important adapter protein for activation of caspase-8 is up-regulated, as is the downstream molecule caspase-2. Yet caspase-lO, often involved in alternate assemblies of the DISC, is down-regulated. The complex regulatory interplay of DISC components is overruled by the down-regulation of Fas and FasL, as they are the primary initiators of DISC assembly. Down-regulation of CD27 is noteworthy as it is vital to the long-term generation and maintenance of T-cell immunity, an important player in atherosclerotic disease. Eight genes were altered by Rl7lE treatment suggesting these are unlikely to be central to the antiinflammatory functions ofSerp-l, Serp-2 and M-T7. Thus the interplay between these apoptotic and immune pathways will require further investigation to assess the overall effects on arterial inflammation, plaque growth and aneurysm formation.
With these studies we examine the potential effects of three viral anti-inflammatory proteins targeting divergent inflammation pathways after angioplasty injury. All three proteins have had prior proven effective anti-inflammatory and anti-atherogenic functions in rodent models. Our findings demonstrate that inhibition of inflammatory responses, irrespective of the inflammatory pathway inhibited, with any of these three different proteins, significantly reduces arterial inflammation, elastic lamina breakage, plaque growth, and aneurysmal dilatation. Further, our findings suggest that these three diverse proteins may cause altered expression and/or activation ofa common downstream pathway, resulting in reduced inflammation, plaque growth and aneurysm-like dilatation of the abdominal aorta. The potential shared effects on apoptotic and inflammatory cell responses ofthese three proteins is mirrored by the detection of a shared cohort of genes with altered expression after treatment of human mononuclear cells with each protein in vitro in tissue culture. These anti-atherogenic and anti-aneurysmal dilatory activities as well as the selected changes in monocyte gene expression were not reproduced by treatment with mutated M-T7 constructs. In summary, the blockade of innate immune responses via differing pathways has the potential to reduce arterial aneurysm-like dilatation and atherosclerotic plaque progression. Investigation of these shared gene targets has the potential for discovery of new therapeutic targets in the apoptotic responses of activated monocytes. I RC I HL I 00202-0 I), and the American Heart Association (0855421 E and 12GRNTl20/0313) for research funding support.
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